08:14 AM EST, 11/04/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported Tuesday a Q3 net loss of $0.38 per diluted share, wider than a loss of $0.22 a year earlier.

Analysts polled by FactSet expected a loss of $0.37.

Revenue for the quarter ended Sept. 30 was $14.5 million, down from $15.4 million a year earlier.

Analysts surveyed by FactSet expected $14.6 million.

As of Sept. 30, the company said it had $344.8 million in cash and or cash equivalents on hand, and expected it could fund operations through 2028.